scholarly journals Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

2021 ◽  
Vol 89 (6) ◽  
pp. 967-974
Author(s):  
MOHAMED IMAM, M.D.; SOLIMAN GHARIB, M.D. ◽  
MOHAMED ABDELGHANY, M.D.; HOSSAM ELHOSSARY, M.D.
Keyword(s):  
Acute Coronary Syndrome ◽  
Short Term ◽  
Coronary Syndrome

scholarly journals Prognostic Value of CA125 Serum Levels in Female Patients with Acute Coronary Syndrome

2021 ◽  
Author(s):  
YanHong Luo ◽  
YongRan Cheng ◽  
XiaoFu Zhang ◽  
MingWei Wang ◽  
Bin Ni ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Coronary Syndrome ◽  
Prognostic Value ◽  
Serum Levels ◽  
Left Ventricular ◽  
Short Term ◽  
Female Patients ◽  
Coronary Syndrome ◽  
Ca125 Level

Abstract Background: carbohydrate antigen 125 (CA125) is an increasingly promising biomarker of heart failure (HF), but its prognostic value in female patients with acute coronary syndrome (ACS) is unclear. We aimed to determine the short-term and mid-term prognostic value of CA125 serum levels in female ACS patients.Methods: A total of 131 consecutive female patients with ACS were retrospective enrolled. Their CA125 levels, B-type natriuretic peptide (BNP) levels and biochemical parameters were measured, and echocardiography was performed at admission. All-cause mortality during hospitalization and two-year follow-up was investigated for the prognosis.Results: The median value of CA125 serum level in the entire ACS patients was 13.85 U/mL. Patients in Killip Ⅲ had the highest values of CA125 level, followed by Killip Ⅱ and then Killip Ⅰ (p < 0.05). However, no statical difference was observed between Killip Ⅳ and Ⅰ-Ⅲ groups respectively (P > 0.05). The CA125 serum levels showed weak positive correlation with left ventricular end-diastolic diameter (LVEDD) (r = 0.3, P < 0.01) and a weak negative correlation with left ventricular ejection fraction (LVEF) (r = –0.23, p < 0.01). A receive operating characteristic (ROC) curve analysis showed that the AUC of CA125 in predicting acute heart failure (AHF) in ACS patients during hospitalization was 0.912, exhibiting higher sensitivity and specificity than BNP (0.846). The optimal cut-off value for CA125 in predicting AHF was 16.4 U/mL with a sensitivity of 0.916 and specificity of 0.893. The Kaplan-Meier survival analysis demonstrated that patients with high values of CA125 level had a poor overall survival than those with low values of CA125 level (log-rank, p < 0.001), whether during hospitalization or mid-term follow-up. Conclusion: Elevated CA125 level can be used to predict AHF in female ACS patients. Patients with elevated CA125 levels had higher mortality in short-term and mid-term than those with low CA125 levels.

scholarly journals Percutaneous vascular closure device of the femoral access site after coronary interventions for acute coronary syndrome -immediate and short term follow-up

2017 ◽  
Vol 5 (3) ◽  
pp. 778 ◽  
Author(s):  
Ashraf Safiya Manzil ◽  
Sidharaj Vala ◽  
Sidharaj Vala
Keyword(s):  
Acute Coronary Syndrome ◽  
Interventional Procedure ◽  
Tertiary Care ◽  
Major Complication ◽  
Coronary Intervention ◽  
Closure Device ◽  
Short Term ◽  
Femoral Access ◽  
Coronary Syndrome

Background: Around 7 million patients undergo percutaneous interventional vascular procedures worldwide annually and this number is expected to escalate further in coming years. The aim of this study was to analyse immediate and short term follow up of patients with acute coronary syndrome (ACS) who had undergone percutaneous coronary intervention (PCI) through femoral route and closure with vascular closure device.Methods: This was non randomised, single centre study and was conducted in a tertiary care institution between January 2013 to June 2014 with 62 ACS patients undergoing femoral access invasive cardiac interventional procedure. Perclose A-T system was used in all patients as closure device. Patients were followed up to 15 days of clinical evaluation.Results: Of 62 ACS patients, 40 (64.5%) were with non-ST elevation myocardial infarction and 22 (35.5%) patients had history of unstable angina. The perclose device achieved closure within 5 to 10 minutes and all patients were kept in hospital stay for 2 to 3 days. There was one major complication of continuous bleeding, one incidence of small pseudo aneurysm, and two incidences of small hematomas with need of blood transfusion.Conclusions: This study demonstrates the ability of arterial closure device to safely and effectively achieve arterial closure in patients undergoing percutaneous intervention for ACS.

Prognostic value of VEGF mRNA expression in short-term follow-up of patients with acute coronary syndrome

2014 ◽  
Vol 24 (1) ◽  
pp. 133-137
Author(s):  
Fadia M. Attia ◽  
Hussein M. Ismail ◽  
Maha Anani ◽  
Amany Moustafa Hassan ◽  
Ranya Morsy
Keyword(s):  
Acute Coronary Syndrome ◽  
Mrna Expression ◽  
Prognostic Value ◽  
Short Term ◽  
Vegf Mrna ◽  
Coronary Syndrome ◽  
Vegf Mrna Expression

Abstract 507: Change in Pulse Wave Velocity and Short Term Development of Cardiovascular Events in the Hemodialysis Population

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Yazan Daaboul ◽  
Serge Korjian ◽  
Balsam El-Ghoul ◽  
Salam Samad ◽  
Pascale Salameh ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Cox Regression ◽  
Hemodialysis Patients ◽  
Short Term ◽  
Coronary Syndrome ◽  
Increased Risk

Objectives: It has previously been demonstrated that single elevated measurements of carotid-femoral pulse wave velocity (CFPWV) among end-stage renal disease (ESRD) patients are associated with an increased risk of cardiovascular (CV) events. However, the association between single measurements of CFPWV and CV events was mostly driven by the high incidence of late events beyond 12 months of follow-up. The present prospective study aims to compare single measurements of CFPWV vs. the 2-year change in CFPWV (delta CFPWV) and their association with short-term development of CV events through 12 months in hemodialysis patients. Methods: Patients on hemodialysis were enrolled for a first measurement of CFPWV (CFPWV t=0 ) followed by a second measurement (CFPWV t=1 ) 2 years ± 1 month later. Patients were then followed up for an additional 12 months for the development of CV events (CV death, acute coronary syndrome, acute ischemic peripheral event necessitating intervention, or stroke). Results: Both CFPWV t=0 and CFPWV t=1 were measured for a total of 66 hemodialysis patients. During the 12-month follow-up period, 13 patients developed a total of 15 events, almost half (7/15) of which were fatal, 4/15 attributed to acute coronary syndrome (ACS), and 4/15 attributed to acute ischemic peripheral artery disease (PAD) necessitating intervention. No stroke events were recorded over the 12-month follow-up duration. Delta CFPWV (CFPWV t=1 - CFPWV t=0 ) was significantly associated with the development of CV events through 12 months with and without adjustment for CV risk factors, including blood pressure parameters (unadjusted: HR=1.22; p=0.001 vs. adjusted: HR=1.14; p=0.002). When delta CFPWV was substituted for either CFPWV t=0 or CFPWV t=1 in both the unadjusted and adjusted Cox regression models, neither measurement was associated with the development of new CV events. Conclusions: The change in CFPWV, but not single measurements of CFPWV, was significantly associated with the short-term development of CV events through 12 months.

scholarly journals Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis

2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Linlin Gu ◽  
Jing Li
Keyword(s):  
Acute Coronary Syndrome ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Continuous Variables ◽  
Short Term ◽  
Coronary Syndrome ◽  
Increased Risk ◽  
All Cause Mortality

Abstract Background: Higher circulating soluble suppression of tumorigenicity-2 (sST2) concentration is suggested as a marker of prognosis in many cardiovascular diseases. However, the short-term and long-term prognostic value of sST2 concentration in acute coronary syndrome (ACS) remains to be summarized. Methods: A meta-analysis of follow-up studies was performed. Studies were identified via systematic search of databases including PubMed, Cochrane’s Library, and Embase. A fixed- or random-effect model was applied according to the heterogeneity. We reported the prognostic value of sST2 concentration for all-cause mortality, heart failure (HF) events, and major adverse cardiovascular events (MACEs) within 1 month after hospitalization and during subsequent follow-up. Results: Twelve studies with 11690 ACS patients were included. Higher baseline sST2 concentration as continuous variables predicte the increased risk of all-cause mortality (risk ratio [RR]: 3.16, P=0.002), HF events (RR: 1.48, P<0.001), and MACEs (RR: 1.47, P<0.001) within 1 month after hospitalization, which is consistent with the results with sST2 concentration as categorized variables (RR = 2.14, 2.89, and 2.89 respectively, P all <0.001). Moreover, higher baseline sST2 concentration as continuous variables predict the increased risk of all-cause mortality (RR: 2.20, P<0.001), HF events (RR: 1.39, P<0.001), and MACEs (RR: 1.53, P=0.02) during subsequent follow-up. Meta-analysis with sST2 concentration as categorized variables retrieved similar results (RR = 2.65, 2.59, and 1.81 respectively, P all <0.001). Conclusions: Higher circulating sST2 concentration at baseline predicts poor clinical outcome in ACS patients.

Sign in / Sign up

Export Citation Format

Share Document